Twitter

Chordate Medical reports Q3 and carries out rights issue – Biostock interviews Anders Weilandt

Chordate’s CEO Anders Weilandt is interviewed by the news service Biostock about the newly released interim report for July-September 2022 and the planned rights issue. Anders Weilandt on the quarter:

” As the most exciting quarter so far in the company’s history – is probably the short answer. First getting the results of the subgroup, and then the analysis of the entire study material, is a confirmation of so many years of hard work and beats most of what the company has experienced. The entire Chordate project has now been “de-risked” down to a completely new and much more comfortable level.”

Read the full interview here.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter